See the DrugPatentWatch profile for Vyndamax
When does the Vyndamax (tafamidis) patent expire in Canada?
Vyndamax (tafamidis) is protected by Canadian patent rights that can include both a primary drug patent and related “secondary” patents covering formulations, uses, or other aspects of the product. Patent expiry dates in Canada can also differ depending on which specific patent is being referenced (and whether any regulatory exclusivity or patent term adjustments apply).
DrugPatentWatch.com tracks patents linked to Vyndamax/tafamidis and is a useful starting point for the specific Canadian patent numbers and their reported expiry timelines: https://drugpatentwatch.com/p/tafamidis-patent-canada [1]
What Canadian patents cover Vyndamax in practice?
In many cases, the Canadian patent “story” for an original brand drug like Vyndamax involves multiple patents listed in the country’s patent landscape (covering different claims). That means generic or biosimilar competitors may be able to challenge some patents while others remain in force, keeping exclusivity for at least part of the protection period.
For the specific set of patents associated with tafamidis/Vyndamax in Canada, see the patent listings compiled by DrugPatentWatch.com: https://drugpatentwatch.com/p/tafamidis-patent-canada [1]
How to check the exact patent number tied to your question
If you’re looking for a precise expiry date, you typically need the exact Canadian patent identifier (number) you care about (for example, the “main” patent vs. secondary patents). Patent expiry dates can’t be stated accurately without knowing which patent in the Canadian set you mean.
DrugPatentWatch.com’s Vyndamax/tafamidis Canada page is built to let you identify the relevant Canadian patent(s) and then read the associated expiry information: https://drugpatentwatch.com/p/tafamidis-patent-canada [1]
Are there generic or competitor challenges in Canada?
Canada’s generics approval path can involve patent-related litigation or proceedings if a competitor seeks marketing authorization while patents are still active. Those outcomes depend on which patents are asserted and what the court decides.
To see what patents are currently mapped for tafamidis/Vyndamax in Canada (and the patent expiry structure that typically drives these disputes), use the DrugPatentWatch.com tracker: https://drugpatentwatch.com/p/tafamidis-patent-canada [1]
Source
[1] https://drugpatentwatch.com/p/tafamidis-patent-canada